In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nephron Pharmaceuticals Corp.

www.nephronpharm.com

Latest From Nephron Pharmaceuticals Corp.

CREATES Act Will Not Lead To Frivolous Lawsuits, Says AAM's Davis

Association for Accessible Medicines' Davis tries to counter concerns that the long-stalled measure would incentivize lawsuits against brand companies; witnesses at a House subcommittee hearing on drug pricing legislation also testified that the BLOCKING Act would create an overly broad and complicated framework for triggering 180-day exclusivity.

Pricing Debate Generic Drugs

CREATES Act: Republican Lawmakers Worry About Frivolous Lawsuits By Generic Firms

Association for Accessible Medicines' Davis tries to counter concerns that the long-stalled measure would incentivize lawsuits against brand companies; witnesses at a House subcommittee hearing on drug pricing legislation also testified that the BLOCKING Act would create an overly broad and complicated framework for triggering 180-day exclusivity.

Pricing Debate Generic Drugs

Deals Shaping The Medical Industry, July 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2016.

BioPharmaceutical Deals

J&J/McNeil Consent Decree Prequel Tops OTC Stories, Switch Leads Topics In 2014

“The Tan Sheet” readers also made top stories of FDA’s rejection of Bayer’s petition for aspirin as primary prevention of heart attack stroke; advisors recommending FDA consider additional label warnings for OTC NSAIDS; and FDA seeking to overhaul its OTC drug monograph process to be “more agile and responsive.”

Consumer United States
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Nephron Pharmaceuticals Corp.
  • Senior Management
  • Contact Info
  • Nephron Pharmaceuticals Corp.
    Phone: (407) 999-2225
    4121 SW 34th St.
    Orlando, FL 32811
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register